Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study

被引：0
|
作者：
Chen, H.
Wang, L.
Wu, Y.
Wu, Y.
Ma, S.
Sen, Y.
Zhen, H.
Mo, Y.
Zhang, C.
Wang, Q.
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
582P
引用
收藏
页码：S1697 / S1697
页数：1
相关论文
共 50 条
  • [31] A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
    Chun-Yao Huang
    Hui-Li Huang
    Chou-Chin Lan
    Yi-Chih Huang
    Yao-Kuang Wu
    BMC Cancer, 23
  • [32] Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations
    Li, Y-S.
    Jiang, B-Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
    Cheng, Wen-Chien
    Shen, Yi-Cheng
    Chen, Chieh-Lung
    Liao, Wei-Chih
    Chen, Chia-Hung
    Chen, Hung-Jen
    Tu, Chih-Yen
    Hsia, Te-Chun
    CANCERS, 2023, 15 (03)
  • [34] Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience
    Zhang, Q.
    Ke, L.
    Huang, S.
    Yang, Y.
    He, T.
    Sun, H.
    Wu, Z.
    Zhang, X.
    Zhang, H.
    Lv, W.
    Hu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S98 - S98
  • [35] Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
    Llinas-Quintero, Nestor
    Gonzalez-Hoyos, David
    Yepes, Andres
    Herrera, Diego A.
    Pelaez-Arroyave, Sebastian
    Caicedo-Zamudio, Carlos
    Blanco-Daza, Erick
    Cuello-Lopez, Javier
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019
  • [36] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
  • [37] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [38] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [39] When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan
    Chen, Chieh-Lung
    Wang, Sing-Ting
    Liao, Wei-Chih
    Chen, Chia-Hung
    Tu, Chih-Yen
    Chen, Hung-Jen
    Hsia, Te-Chun
    Cheng, Wen-Chien
    BMC CANCER, 2022, 22 (01)
  • [40] Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
    Molife, Cliff
    Cho, Jae Min
    Lapthorn, Jennifer
    Kang, Min Ju
    D'yachkova, Yulia
    Kim, Sangmi
    Colman, Sam
    Kim, Saerom
    Szende, Agota
    Park, Ji Hyun
    Ahn, Hee Kyung
    Hong, Min Hee
    Taipale, Kaisa-Leena
    Kim, Hye Ryun
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (01) : 131 - 143
12345